Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment

Presenter: Stephen D. Smith
Restricted access

Although sharing some common features in terms of etiology and even clinical presentation, marginal zone lymphoma is a heterogeneous group of diseases, with subtypes that can present in unexpected ways, especially with regard to autoimmune disease. There’s a proven role of antimicrobial therapy for both Helicobacter pylori and hepatitis C virus, and 10-year overall survival is high. Because this disease requires continuous treatment, therapy should be properly sequenced, with consideration given to patient comorbidities and age. Finally, B-cell receptor signaling inhibitors and immunomodulatory agents can provide responses and disease control.

Disclosures: Dr. Smith has disclosed that he receives grant/research support from Acerta Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, BeiGene, Denovo Biopharma, Genentech, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Pharmacyclics, and Portola Pharmaceuticals, Inc.; receives consulting fees from AstraZeneca Pharmaceuticals LP, Denovo Biopharma, Genentech, Inc., Kite Pharma, and Millennium Pharmaceuticals, Inc.; and is a scientific advisor for BeiGene. Dr. Smith also discloses that his spouse receives consulting fees from Ayala and Bristol-Myers Squibb, and grant/research support from Ayala, Bristol-Myers Squibb Company, Ignyta, and Incyte Corporation.

Correspondence: Stephen D. Smith, MD, University of Washington/Fred Hutchinson Cancer Research Center, 617 Eastlake Avenue E, CE3-300, Seattle, WA 98109. Email: ssmith50@seattlecca.org
  • 1.

    Rummel MJ, Niederle N, Maschmeyer G, et al. . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:12031210.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Baldini L, Brugiatelli M, Luminari S, et al. . Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 2003;21:14591465.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Zucca E, Conconi A, Martinelli G, et al. . Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol 2017;35:19051912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Salar A, Domingo-Domenech E, Panizo C, et al. . First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol 2014;1:e104111.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Williams ME, Hong F, Gascoyne RD, et al. . Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 2016;173:867875.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood 2016;127:20722081.

  • 7.

    Kalpadakis C, Pangalis GA, Sachanas S, et al. . Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood 2018;132:666670.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Noy A, de Vos S, Thieblemont C, et al. . Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:22242232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Sacchi S, Marcheselli R, Bari A, et al. . Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica 2016;101:e196199.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Kiesewetter B, Willenbacher E, Willenbacher W, et al. . A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood 2017;129:383385.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Leonard JP, Trneny M, Izutsu K, et al. . AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:11881199.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Zelenetz AD, Gordon LI, Abramson JS, et al. . NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. Version 4.2020. Accessed October 19, 2020. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 13.

    Zucca E, Arcaini L, Buske C, et al. . Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1729.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 689 689 33
PDF Downloads 251 251 32
EPUB Downloads 0 0 0